A Phase 1, Open-Label Dose Escalation and Expansion Study of PT0253 in Participants with KRAS G12D Mutated Advanced Solid Tumors
Latest Information Update: 03 Feb 2025
Price :
$35 *
At a glance
- Drugs PT 0253 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors PAQ Therapeutics
- 03 Feb 2025 New trial record